ORAI1, FGF23, PP13, Palladin, and Supervillin as Potential Biomarkers in Late-Onset Pre- eclampsia: A Comparative Study in Maternal and Cord Blood Running Title: Potential Biomarkers in Late-Onset Pre-eclampsia DOI
Hatice Argun Atalmis, Sinem Tekin, İbrahim Yılmaz

et al.

Research Square (Research Square), Journal Year: 2025, Volume and Issue: unknown

Published: April 25, 2025

Abstract Background Pre-eclampsia continues to be a significant global health burden with complex pathophysiology, necessitating investigation of novel biomarkers improve understanding, diagnosis and management this pregnancy-specific disorder.To investigate the differential expression Calcium Release-Activated Channel Protein 1 (ORAI1), Fibroblast Growth Factor 23 (FGF23), Placental 13 (PP13), Palladin, Supervillin in both maternal umbilical cord blood as potential for late-onset pre-eclampsia. Methods This cross-sectional, case-control study included 61 women pre-eclampsia normotensive pregnant undergoing cesarean delivery. Maternal samples were collected immediately prior delivery, was obtained after delivery placenta. concentrations circulatory compartments measured using enzyme-linked immunosorbent assay. The unique design paired maternal-cord sampling provided insights into maternal-fetal protein transfer dynamics pre-eclamptic conditions. Results ORAI1 significantly elevated (p = 0.001 p 0.035, respectively), while FGF23 PP13 decreased 0.022 0.018, respectively). Maternal-to-cord concentration ratios altered 0.038 0.021, showed highest diagnostic accuracy (AUC 0.733) correlated positively disease severity negatively birth weight. Combined assessment enhanced performance 0.782). Conclusion ORAI1, FGF23, suggests disruptions calcium signaling, phosphate metabolism, placental function. parallel measurement these proteins interface dysfunction superior combined underscores value multi-marker approach capturing pre-eclampsia's potentially contributing improved strategies therapeutic interventions.

Language: Английский

Role of Ca2+/calmodulin and PI3K/AKT signaling pathways and active ingredients of BaoTaiYin in treatment of recurrent miscarriage DOI Creative Commons
Ji Li,

Anqi Deng,

Huiying Chen

et al.

Frontiers in Molecular Biosciences, Journal Year: 2025, Volume and Issue: 12

Published: March 25, 2025

Introduction BaoTaiyin (BTY) is a traditional Chinese medicine decoction. It has been used to treat recurrent miscarriage (RM). However, there are no comprehensive systematic studies identify the chemical compositions of BTY and molecular mechanisms on RM. Finding components clarifying underlying processes in treatment RM were goals study. Methods We ultra-high-performance liquid chromatography coupled with triple quadruple time-of-flight tandem mass spectrometry analyze BTY, network analysis predict pharmacological effects identified active ingredients, cell experiments potential mechanisms. Results found 12 ingredients among 61 BTY. These activities linked regulatory 127 key signaling pathways, targeting 107 proteins. Through analysis, we determined that insulin-like growth factor 1 receptor, matrix metalloproteinases, PI3K, STAT3 may be core targets BTY’s therapeutic further explored this mechanism find aqueous extracts significantly enhanced IGFBP2 CaMKK2 expression trophoblast proliferation, whereas inhibitors IGF1R/PI3K/AKT pathway or blocked effect proliferation. In addition, siRNA suppressed BTY-induced expression. Caffeic acid, as one increased intracellular Ca 2+ concentration proliferation trophoblast. Conclusion Our research showed have benefits through multiple such /calmodulin pathways.

Language: Английский

Citations

0
ORAI1, FGF23, PP13, Palladin, and Supervillin as Potential Biomarkers in Late-Onset Pre- eclampsia: A Comparative Study in Maternal and Cord Blood Running Title: Potential Biomarkers in Late-Onset Pre-eclampsia DOI
Hatice Argun Atalmis, Sinem Tekin, İbrahim Yılmaz

et al.

Research Square (Research Square), Journal Year: 2025, Volume and Issue: unknown

Published: April 25, 2025

Abstract Background Pre-eclampsia continues to be a significant global health burden with complex pathophysiology, necessitating investigation of novel biomarkers improve understanding, diagnosis and management this pregnancy-specific disorder.To investigate the differential expression Calcium Release-Activated Channel Protein 1 (ORAI1), Fibroblast Growth Factor 23 (FGF23), Placental 13 (PP13), Palladin, Supervillin in both maternal umbilical cord blood as potential for late-onset pre-eclampsia. Methods This cross-sectional, case-control study included 61 women pre-eclampsia normotensive pregnant undergoing cesarean delivery. Maternal samples were collected immediately prior delivery, was obtained after delivery placenta. concentrations circulatory compartments measured using enzyme-linked immunosorbent assay. The unique design paired maternal-cord sampling provided insights into maternal-fetal protein transfer dynamics pre-eclamptic conditions. Results ORAI1 significantly elevated (p = 0.001 p 0.035, respectively), while FGF23 PP13 decreased 0.022 0.018, respectively). Maternal-to-cord concentration ratios altered 0.038 0.021, showed highest diagnostic accuracy (AUC 0.733) correlated positively disease severity negatively birth weight. Combined assessment enhanced performance 0.782). Conclusion ORAI1, FGF23, suggests disruptions calcium signaling, phosphate metabolism, placental function. parallel measurement these proteins interface dysfunction superior combined underscores value multi-marker approach capturing pre-eclampsia's potentially contributing improved strategies therapeutic interventions.

Language: Английский

Citations

0